818 Stock Overview
A medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Zylox-Tonbridge Medical Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.53 |
| 52 Week High | HK$1.57 |
| 52 Week Low | HK$1.50 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -2.55% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -74.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 818 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | 0.5% |
| 1Y | n/a | -7.5% | 7.2% |
Return vs Industry: Insufficient data to determine how 818 performed against the German Medical Equipment industry.
Return vs Market: Insufficient data to determine how 818 performed against the German Market.
Price Volatility
| 818 volatility | |
|---|---|
| 818 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 818 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 818's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 594 | Jonathon Zhao | www.zyloxtb.com |
Zylox-Tonbridge Medical Technology Co., Ltd., a medical device company, provides neuro- and peripheral-vascular interventional medical devices the People’s Republic of China and internationally. The company develops neurovascular product portfolio that covers a suite of products for various categories, including ischemic stroke, hemorrhagic stroke, stenosis, carotid artery, and vascular access device. It also develops peripheral-vascular interventional product portfolio covering a spectrum of arterial and venous products comprising stents, balloons, catheters, and filters, as well as covers hemodialysis access, aortic intervention, peripheral embolization intervention, and radiological intervention products.
Zylox-Tonbridge Medical Technology Co., Ltd. Fundamentals Summary
| 818 fundamental statistics | |
|---|---|
| Market cap | €449.48m |
| Earnings (TTM) | -€21.10m |
| Revenue (TTM) | €35.18m |
12.8x
P/S Ratio-21.3x
P/E RatioIs 818 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 818 income statement (TTM) | |
|---|---|
| Revenue | CN¥259.17m |
| Cost of Revenue | CN¥63.94m |
| Gross Profit | CN¥195.23m |
| Other Expenses | CN¥350.71m |
| Earnings | -CN¥155.48m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Mar 29, 2023
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 75.33% |
| Net Profit Margin | -59.99% |
| Debt/Equity Ratio | 0% |
How did 818 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/20 03:18 |
| End of Day Share Price | 2022/12/22 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zylox-Tonbridge Medical Technology Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shuo Song | Citic Securities Co., Ltd. |
| null null | Guoyuan Securities (HK) Ltd |
| Youjue Hu | Morgan Stanley |